The CDMO has invested in its Le Mans, France site, which it contends is one of the world’s leading facilities for antibody-drug conjugate and cytotoxic drug manufacturing.
The proposal also includes $9 million and 19 new full-time positions for the U.S. Food and Drug Administration to accelerate advanced pharmaceutical manufacturing.
The facility, slated to be GMP-ready in 2027, will house one of Japan’s largest single-use bioreactor systems for mammalian production, according to the company.
AI is helping life sciences manufacturers improve uptime, PM effectiveness, calibration planning, and reliability analysis. See where practical AI adds value in GMP asset management...
Lilly’s total Chinese investment has reached nearly $6 billion, including $3 billion over the next decade to build a localized manufacturing and supply network.
The biopharmaceutical industry’s funding trends, product pipeline, and pace of R&D spending indicate demand is set to improve this year, say William Blair analysts.
Biopharma companies are increasingly choosing to outsource manufacturing for the U.S. market to European facilities, finds data and analytics firm GlobalData.
While its advanced synthesis and integrated biologics platforms drove strong growth in 2025, the company’s specialized modalities sales declined versus the prior year.
Leerink Partners analysts see no near-term material changes to U.S. onshoring narrative, given Trump’s executive order late last week on pharmaceutical imports.
Drug companies with Most Favored Nation pricing deals with the Trump administration are exempt, as are generic drugs, biosimilars, and related ingredients.
The CDMO says the pending acquisition of two U.S. drug substance facilities, slated to close in the second or third quarter, positions it for sustained profitable growth.
The company is strengthening development and manufacturing offerings, says Anil Kane, global head of technical and scientific affairs for Thermo Fisher’s pharma services.
The South Korean company claims that its Syracuse Bio Campus, a former Bristol Myers Squibb facility, has one of the largest U.S. conjugation capabilities for ADC production.
With the installation of large-scale stainless steel and smaller single-use bioreactors, Fujifilm Biotechnologies is expanding into drug products and finished goods.
The Gwinnett County campus will implement a digital-first approach leveraging AI, robotics, and automation to produce biologics primarily for the U.S. market.
The Chinese CRDMO’s revenue generated from the U.S. market increased $34.3% year-over-year, while Europe and China declined last year compared to 2024.
By pairing AMTs with underutilized U.S. facilities, APIIC aims to expand domestic manufacturing of critical medicines and strengthen pharmaceutical supply chain.
As part of its $15 billion investment in China, the drugmaker intends to become the first global biopharma company with end-to-end cell therapy capabilities in the country.
Chinese production of active pharmaceutical ingredients and key starting materials is putting Americans at risk, according to a bipartisan congressional committee.
The new biomanufacturing campus in Holly Springs, North Carolina was modelled after a large-scale production site in Hillerød, Denmark, cutting design time by 70%.
Guidance reflects customer loss due to change in its supply strategy, lower hyaluronic acid revenue from customer, and delayed customer launch that was slated for this year.
The agency cited the CDMO’s significant violations of current Good Manufacturing Practice regulations for finished pharmaceuticals at Simtra’s Halle/Westfalen facility.
These therapies are poised to reshape treatment standards this year, from next‑gen metabolic drugs to breakthrough advances in oncology, immunology, and rare diseases.
The 125,000-square-foot facility, which is slated to be operational in 2027, is where cutting-edge genetic medicine will meet industrial scale, says CEO Chris Murphy.